Lite Strategy (LITS) Non Operating Income (2022 - 2026)
Lite Strategy (LITS) posted quarterly Non Operating Income of -$2.1 million for Q1 2026, down 1136.82% year-over-year from $201000.0 in Q1 2025, and down 123.61% quarter-over-quarter from -$932000.0 in Q4 2025.
Lite Strategy (LITS) Non Operating Income (2022 - 2026) Analysis & Trends
Lite Strategy's Non Operating Income history runs 5 years deep, the most recent figure standing at -$2.1 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 1136.82% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$2.7 million (down 243.93% YoY), while the FY2025 annual figure was $1.5 million, down 53.34% from the prior year.
- Non Operating Income for Q1 2026 stood at -$2.1 million, down from -$932000.0 in the prior quarter.
- The five-year high for Non Operating Income was $1.6 million in Q3 2022, with the low at -$2.1 million in Q1 2026.
- The 5-year median for Non Operating Income is $702000.0 (2024), against an average of $450400.0.
- The sharpest annual moves came in 2024 and 2026: Non Operating Income decreased 10.73% in 2024, then plunged 1136.82% in 2026.
- Lite Strategy's Non Operating Income stood at $1.3 million in 2022, then tumbled by 34.66% to $867000.0 in 2023, then fell by 10.73% to $774000.0 in 2024, then sank by 220.41% to -$932000.0 in 2025, then slumped by 123.61% to -$2.1 million in 2026.
- Business Quant data shows LITS's Non Operating Income at -$2.1 million in Q1 2026, -$932000.0 in Q4 2025, and $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | -2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.08 Mn |
| Dec 31, 2025 | -932,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 190,000.00 |
| Mar 31, 2025 | 201,000.00 |
| Dec 31, 2024 | 774,000.00 |
| Sep 30, 2024 | 345,000.00 |
| Jun 30, 2024 | 574,000.00 |
| Mar 31, 2024 | 702,000.00 |
| Dec 31, 2023 | 867,000.00 |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | 953,000.00 |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | 1.60 Mn |